- Title
- Experimental and human evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin NGAL ) in the development of cardiac hypertrophy and heart failure
- Creator
- Marques, Francine; Prestes, Priscilla; Byars, Sean; Ritchie, Scott; Wurtz, Peter; Patel, Sheila; Booth, Scott; Rana, Indrajeetsinh; Minoda, Yosuke; Berzins, Stuart; Curl, Claire; Bell, James; Wai, Bryan; Srivastava, Piyush; Kangas, Antti; Soininen, Pasi; Ruohonen, Saku; Kahonen, Mika; Lehtimaki, Terho; Raitoharju, Emma; Havulinna, Aki; Perola, Markus; Raitakari, Olli; Salomaa, Veikko; Ala-Korpela, Mika; Kettunen, Johannes; McGlynn, Maree; Kelly, Jason; Wlodek, Mary; Lewandowski, Paul; Delbridge, Lea; Burrell, Louise; Inouye, Michael; Harrap, Stephen; Charchar, Fadi
- Date
- 2017
- Type
- Text; Journal article
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/159271
- Identifier
- vital:11958
- Identifier
-
https://doi.org/10.1161/jaha.117.005971
- Identifier
- ISSN:2047-9980
- Abstract
- Background-Cardiac hypertrophy increases the risk of developing heart failure and cardiovascular death. The neutrophil inflammatory protein, lipocalin-2 (LCN2/NGAL), is elevated in certain forms of cardiac hypertrophy and acute heart failure. However, a specific role for LCN2 in predisposition and etiology of hypertrophy and the relevant genetic determinants are unclear. Here, we defined the role of LCN2 in concentric cardiac hypertrophy in terms of pathophysiology, inflammatory expression networks, and genomic determinants. Methods and Results-We used 3 experimental models: a polygenic model of cardiac hypertrophy and heart failure, a model of intrauterine growth restriction and Lcn2-knockout mouse; cultured cardiomyocytes; and 2 human cohorts: 114 type 2 diabetes mellitus patients and 2064 healthy subjects of the YFS (Young Finns Study). In hypertrophic heart rats, cardiac and circulating Lcn2 was significantly overexpressed before, during, and after development of cardiac hypertrophy and heart failure. Lcn2 expression was increased in hypertrophic hearts in a model of intrauterine growth restriction, whereas Lcn2-knockout mice had smaller hearts. In cultured cardiomyocytes, Lcn2 activated molecular hypertrophic pathways and increased cell size, but reduced proliferation and cell numbers. Increased LCN2 was associated with cardiac hypertrophy and diastolic dysfunction in diabetes mellitus. In the YFS, LCN2 expression was associated with body mass index and cardiac mass and with levels of inflammatory markers. The single-nucleotide polymorphism, rs13297295, located near LCN2 defined a significant cis-eQTL for LCN2 expression. Conclusions-Direct effects of LCN2 on cardiomyocyte size and number and the consistent associations in experimental and human analyses reveal a central role for LCN2 in the ontogeny of cardiac hypertrophy and heart failure.
- Publisher
- American Heart Association
- Relation
- Journal of the American Heart Association Vol. 6, no. 6 (2017), p. 1-58; http://purl.org/au-research/grants/nhmrc/1034371
- Rights
- http://creativecommons.org/licenses/by-nc/4.0/
- Rights
- Copyright © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- Rights
- Open Access
- Rights
- This metadata is freely available under a CCO license
- Subject
- 1102 Cardiorespiratory Medicine and Haematology; Concentric hypertrophy; C-reactive protein; Gene coexpression networks; GlycA; Hypertrophy; Lipocalin-2; NGAL; Systems biology
- Full Text
- Reviewed
- Hits: 49110
- Visitors: 42126
- Downloads: 403
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Published version | 3 MB | Adobe Acrobat PDF | View Details Download |